Venous thromboembolism in non-small cell lung cancer patients who underwent surgery after induction therapy

• Published in: General thoracic and cardiovascular surgery 2020-10, Vol.68 (10), p.1156-1162
• Main Authors: Kaminuma, Yasunori, Tanahashi, Masayuki, Suzuki, Eriko, Yoshii, Naoko, Niwa, Hiroshi
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anticoagulants; Anticoagulants - therapeutic use; Asymptomatic; Cancer therapies; Carcinoma, Non-Small-Cell Lung - complications; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - surgery; Cardiac Surgery; Cardiology; Chemotherapy; Female; Heparin - therapeutic use; Histology; Humans; Incidence; Induction Chemotherapy; Induction therapy; Lung cancer; Lung Neoplasms - complications; Lung Neoplasms - drug therapy; Lung Neoplasms - surgery; Lymphatic system; Male; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Neoplasm Recurrence, Local - complications; Original; Original Article; Patients; Radiation; Retrospective Studies; Risk Factors; Surgery; Surgical Oncology; Thoracic Surgery; Thromboembolism; Tomography; Tumors; Venous Thromboembolism - etiology; Venous Thromboembolism - prevention & control; Venous Thrombosis - prevention & control
• ISSN: 1863-6705; 1863-6713
• DOI: 10.1007/s11748-020-01351-0

Objectives Lung cancer patients have been reported to have a high incidence of venous thromboembolism (VTE) and a high recurrence rate of VTE. However, there are no detailed reports of VTE in lung cancer patients who underwent surgery after induction therapy. We examined the incidence and clinical features of VTE in these patients. Methods We retrospectively evaluated 89 patients with non-small cell lung cancer who underwent surgery after induction therapy at our department between April 2009 and March 2018. The incidence of VTE, clinical features, and long-term prognosis were retrospectively examined. Results Among the 89 patients, 4 (4.5%) developed VTE, and there was no significant difference in the background characteristics between patients with and without VTE. All four patients developed VTE during preoperative treatment. In the patients with VTE, anticoagulant therapy with oral anticoagulants was administered after heparinization, and the median duration of anticoagulant therapy was 18.7 months. There were no cases of symptomatic VTE recurrence after surgery, regardless of lung cancer recurrence. Although the overall survival (OS) showed no significant difference between patients with and without VTE, the disease-free survival was significantly shorter in patients with VTE than in those without it (median 6.3 vs. 71.6 months, p